Ionis to hold first quarter 2023 financial results webcast
Ionis Pharmaceuticals has announced a live webcast scheduled for May 3, 2023, at 11:30 a.m. Eastern Time, to discuss its first quarter 2023 financial results.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ionis Pharmaceuticals has announced a live webcast scheduled for May 3, 2023, at 11:30 a.m. Eastern Time, to discuss its first quarter 2023 financial results. This event will provide insights into the company's financial performance, emphasizing its leadership in RNA-targeted therapies. Ionis has over three decades of experience and currently boasts three marketed medicines alongside a robust late-stage pipeline focused on cardiovascular and neurological treatments. Stakeholders can access the webcast and follow up with a replay through Ionis' investor relations page.
Positive
- Ionis has over 30 years of experience in RNA-targeted therapy.
- The company has three marketed medicines.
- The late-stage pipeline includes cardiovascular and neurological franchises.
Negative
- None.
Details
News Market Reaction – IONS
The recorded move for IONS in the trading session of this news was -1.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast scheduled for
The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
About
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-hold-first-quarter-2023-financial-results-webcast-301802455.html
SOURCE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.